0.75p-0.03 (-3.23%)30 Jan 2025, 16:27
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

Valirx PLC Fundamentals

Company NameValirx PLCLast Updated2025-01-30
IndustryBiotechnologySectorHealthcare
Shares in Issue374.349 mMarket Cap£2.81 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-£0.02EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.0046Debt Equity Ratio0.0017
Asset Equity Ratio1.0536Cash Equity Ratio0.2309
Quick Ratio5.0169Current Ratio6.65
Price To Book Value0.7296ROCE0

Valirx PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Valirx PLC Company Financials

Assets20232022
Tangible Assets£242,625.00£5,561.00
Intangible Assets£2.32 m£2.51 m
Investments00
Total Fixed Assets£2.56 m£2.51 m
Stocks£69,002.000
Debtors£99,050.00£76,228.00
Cash & Equivalents£174,684.00£1.14 m
Other Assets00
Total Assets£3.13 m£3.98 m
Liabilities20232022
Creditors within 1 year£214,654.00£127,575.00
Creditors after 1 year£11,857.00£22,070.00
Other Liabilities00
Total Liabilities£226,511.00£149,645.00
Net assets£2.90 m£3.83 m
Equity20232022
Called up share capital£102,320.00£90,174.00
Share Premium£27.87 m£26.77 m
Profit / Loss-£2.30 m-£2.60 m
Other Equity£3.22 m£4.05 m
Preference & Minorities-£314,623.00-£224,539.00
Total Capital Employed£2.90 m£3.83 m
Ratios20232022
Debt Ratio£0.00£0.01
Debt-to-Equity£0.00£0.01
Assets / Equity1.05361.0536
Cash / Equity0.23090.2309
EPS-£0.02-£0.03
Cash Flow20232022
Cash from operating activities-£1.77 m-£1.71 m
Cashflow before financing-£656,612.00£543,805.00
Increase in Cash-£962,793.00£543,805.00
Income20232022
Turnover£9,600.000
Cost of sales£1,440.000
Gross Profit£8,160.000
Operating Profit-£2.30 m-£2.59 m
Pre-Tax profit-£2.30 m-£2.60 m

Valirx PLC Company Background

SectorHealthcare
ActivitiesValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers,specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, VAL401 for lung cancer, VAL301, BC201, CLX001, and other drug candidates in their different stages of development.
Latest Interim Date27 Sep 2024
Latest Fiscal Year End Date15 May 2024

Valirx PLC Directors

AppointedNamePosition
2013-10-08Mr. James Nicholas ThornileyNon-Executive Director,Chairman
2020-04-14Dr. George MorrisExecutive Director,Chief Operating Officer
2020-04-14Dr. Satu VainikkaExecutive Director,Chief Executive Officer
2024-12-30Mr. Gerald DeslerExecutive Director,Chief Financial Officer and Company Secretary
2022-06-30Mr. Kevin J AlexanderNon-Executive Director,Company Secretary
2010-04-01Dr. Jacob MicallefExecutive Director,Chief Technical Officer
2024-04-15Ms. Stella PanuNon-Executive Director
2007-10-25Mr. Anthony Roger MooreNon-Executive Director,Chairman
2020-07-03Mr. Oliver de Giorgio-MillerNon-Executive Director,Chairman
2025-01-09Dr. Mark Edward EcclestonExecutive Director,Chief Executive Officer
2019-05-31Mr. Seppo Olavi MakinenNon-Executive Director
2024-10-18Mr. Martin LampshireNon-Executive Director
2024-08-15Dr. Suzanne Dilly Executive Director
2024-06-19Dr. Kevin Paul Cox Non-Executive Director,Chairman
2024-12-30Mr. Martin John GouldstoneNon-Executive Director,Chairman
2024-12-30Mr. Adrian Michael Patrick de CourceyNon-Executive Director
2024-12-30Ms. Catherine Jane Tralau-StewartExecutive Director,Chief Scientific Officer

Valirx PLC Contact Details

Company NameValiRx PLC
Address16 Upper Woburn Place, London, WC1H 0BS
Telephone+44 2030084416
Websitehttps://www.valirx.com

Valirx PLC Advisors

StockbrokerBeaufort Securities Ltd
Phone+44 2073828300
Fax+44 2073828400
SolicitorPinsent Masons LLP
Phone+44 2074187000
Fax+44 2074187050
AuditorAdler Shine LLP
Phone+44 2083713000
Fax+44 2083713099
BankRoyal Bank of Scotland PLC
Financial PR AdviserPeckwater PR
RegistrarCapita Asset Services
Phone+44 8704027573
Nominated AdviserCairn Financial Advisers LLP
Phone+44 2072130880